Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-421 Subcutaneous Formulation in HIV Infected Adults
NCT04620291Phase 1Not yet recruiting
- Sponsor
- United BioPharma
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- IgG Antibodies
01
Overview
Phase 1, open-label trial of semzuvolimab in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by United BioPharma. Primary endpoint: Treatment-Emergent Adverse Events at 28 days. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
semzuvolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04620291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620291.